Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors
An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.
Previous Post
Cardinal Health to Acquire Solaris Health for $1.9B to Expand Urology Focus
Next Post
KFF/ESPN Survey of 1988 NFL Players Finds the Vast Majority Say Pro Football Left Them With a Range of Serious Health Problems, but Most Would Play Again and Encourage Their Kids To Play
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago